• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
185735 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州

8 g: A, J5 j' S8 L- E* L# {# m  W, m可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  ; e, H& o6 q- Z5 a
/ b0 a& ?- L( h5 E  Z5 F* Y
( a# A2 v. Z% B7 H6 h  j; W
Sub-category:1 o# k% j: z" w% w0 h5 T
Molecular Targets , g3 x- C9 L- J/ a4 I' M1 d

( _/ I1 {2 @7 g7 ~
: [9 T) E" m4 d7 `4 d7 NCategory:
/ X/ x) M: h0 s  sTumor Biology
9 X' F6 Q4 ?4 _% U5 A. E. K
, z- i$ s- F" t3 f9 S5 U+ D* t% h$ ^+ h/ M# S' e: E+ g
Meeting:
* t5 V. Z; f7 v2011 ASCO Annual Meeting
3 r0 P$ V3 Y3 W8 Z. K  \# ?8 a# w2 U* ?* k! ~# k1 A; y& Z* R

% o: h/ f7 {: Y9 ~Session Type and Session Title:
! R, F- M( W2 ^, U6 ?Poster Discussion Session, Tumor Biology
' G4 ?( g! k0 g% \- L
: M" [- F2 r. o3 b4 N# G8 b8 Z$ G' F4 C; I  M1 ^$ K
Abstract No:5 T- N$ P$ ~7 r- I& s( e
10517
" f7 t- e+ |( q" w0 m  C4 {6 {2 x/ r' h! l( d* h( @# K' p

" l+ Y  @% D5 k+ g- K# E  e- RCitation:
& q3 O5 X( G% [" N1 R( W, MJ Clin Oncol 29: 2011 (suppl; abstr 10517) 3 D4 G  k2 ]! L% Y5 R

* X2 _1 Q: p/ ?" {% r) K- [: v  C% w
Author(s):
5 W% X3 w5 t' S+ I! @* WJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
6 M( M8 \* T5 y
6 D! X. k( @4 J5 [9 N# L8 a
6 W' d$ }9 v. }: @: k0 _& Q: y
. k  ~: {" Q" z) x$ G. ~" E+ M3 N* n- oAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.1 C% L! N0 ~4 H

$ x. W3 `/ \; k7 a3 R2 qAbstract Disclosures/ w$ S& ?! \9 Q& E
% C9 H, ?+ A- d3 U3 x" _
Abstract:, }! \! x2 I' J; o! O

" B3 v$ w2 a% [' `! ?# U7 ?) B4 w
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
$ s+ q' K7 i+ S3 `. @
: Q5 O* O! ]* Z& M # c! x! z9 }# `/ ~7 x0 v
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 1 ?4 Q: T1 b$ T6 G- T- W$ W
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

5 f5 d6 T& }! J4 D9 N/ f化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 * m* g& E/ {& R1 B. j$ U
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。+ P' p: p1 {3 G3 x; h7 T
ALK一个指标医院要900多 ...
* m, h% @; ~3 |' U9 `6 n
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
; R- A8 d+ A2 M; u
# Z5 f. f6 I9 A* q) a7 `: f- ~现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表